BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 29777201)

  • 21. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
    Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin E1 Inhibits
    Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
    Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus vector-mediated Gli1 siRNA induces growth inhibition and apoptosis in human pancreatic cancer with Smo-dependent or Smo-independent Hh pathway activation in vitro and in vivo.
    Guo J; Gao J; Li Z; Gong Y; Man X; Jin J; Wu H
    Cancer Lett; 2013 Oct; 339(2):185-94. PubMed ID: 23791879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
    Gruber W; Peer E; Elmer DP; Sternberg C; Tesanovic S; Del Burgo P; Coni S; Canettieri G; Neureiter D; Bartz R; Kohlhof H; Vitt D; Aberger F
    Int J Cancer; 2018 Mar; 142(5):968-975. PubMed ID: 29055107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
    Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
    Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
    PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Smoothened is a poor prognosis factor and a potential therapeutic target in glioma.
    Tu Y; Niu M; Xie P; Yue C; Liu N; Qi Z; Gao S; Liu H; Shi Q; Yu R; Liu X
    Sci Rep; 2017 Feb; 7():42630. PubMed ID: 28195165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol.
    Wang F; Stappenbeck F; Matsui W; Parhami F
    J Cell Biochem; 2017 Mar; 118(3):499-509. PubMed ID: 27490478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overcoming the resistance mechanisms of Smoothened inhibitors.
    Dong X; Wang C; Chen Z; Zhao W
    Drug Discov Today; 2018 Mar; 23(3):704-710. PubMed ID: 29326074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.
    Chenna V; Hu C; Pramanik D; Aftab BT; Karikari C; Campbell NR; Hong SM; Zhao M; Rudek MA; Khan SR; Rudin CM; Maitra A
    Mol Cancer Ther; 2012 Jan; 11(1):165-73. PubMed ID: 22027695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth.
    Wang J; Peng Y; Liu Y; Yang J; Ding N; Tan W
    BMC Cancer; 2015 Aug; 15():595. PubMed ID: 26296751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gant61 ameliorates CCl
    Jiayuan S; Junyan Y; Xiangzhen W; Zuping L; Jian N; Baowei H; Lifang J
    Toxicol Appl Pharmacol; 2020 Jan; 387():114853. PubMed ID: 31816328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
    Peluso MO; Campbell VT; Harari JA; Tibbitts TT; Proctor JL; Whitebread N; Conley JM; White KF; Kutok JL; Read MA; McGovern K; Faia KL
    PLoS One; 2014; 9(3):e90534. PubMed ID: 24608250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
    Larsen AR; Bai RY; Chung JH; Borodovsky A; Rudin CM; Riggins GJ; Bunz F
    Mol Cancer Ther; 2015 Jan; 14(1):3-13. PubMed ID: 25376612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
    Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
    Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth.
    Campbell VT; Nadesan P; Ali SA; Wang CY; Whetstone H; Poon R; Wei Q; Keilty J; Proctor J; Wang LW; Apte SS; McGovern K; Alman BA; Wunder JS
    Mol Cancer Ther; 2014 May; 13(5):1259-69. PubMed ID: 24634412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective targeting of Hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective Smoothened antagonist that penetrates the blood-brain barrier.
    Rohner A; Spilker ME; Lam JL; Pascual B; Bartkowski D; Li QJ; Yang AH; Stevens G; Xu M; Wells PA; Planken S; Nair S; Sun S
    Mol Cancer Ther; 2012 Jan; 11(1):57-65. PubMed ID: 22084163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.